Dexmethylphenidate · Focalin, Focalin Xr

What is Dexmethylphenidate?

Dexmethylphenidate is the active d-enantiomer of methylphenidate, a CNS stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the extracellular space.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Focalin, Focalin Xr, CTx-1301

Drug type

Small molecule

Targets

dopamine transporter (SLC6A3) (secondary target), norepinephrine transporter (SLC6A2) (secondary target)

Mechanism

Inhibitor of dopamine transporter (SLC6A3)

Therapy area

Psychiatry

Developer

Sandoz

In trials of

CING

FDA status

Approved as Focalin, Focalin Xr (November 13, 2001), NDA021278 · FDA label

UNII

M32RH9MFGP

✅ FDA-approved uses

• Attention Deficit Hyperactivity Disorder (ADHD) (Focalin Xr)
• Attention Deficit Hyperactivity Disorder (ADHD) (Focalin)

From the indications section of the FDA label (version of Sep 23, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ADHDHealthy Volunteers in Fed and Fasted State

Other drugs acting on SLC6A3

Sources

• FDA label (DailyMed)
• FDA label Focalin Xr (2025-09-23), indications
• FDA label Focalin (2024-05-30), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT04138498
• ClinicalTrials.gov NCT04138498
• ClinicalTrials.gov NCT07119073

Updated Oct 3, 2026.